RAN Translation Control via PKR and eIF2α Phosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism of repeat-associated non-ATG (RAN) translation has not been well understood, leading to challenges in addressing the protein toxicity associated with diseases such as Huntington's disease and amyotrophic lateral sclerosis, where RAN proteins accumulate and cause cellular dysfunction.
Innovation Solution
Inhibition of eukaryotic initiation factor 2-alpha (eIF2α) phosphorylation and/or expression of alternative eIF2A, or inhibition of Protein Kinase R (PKR), using agents like eIF2 modulators or PKR inhibitors, to reduce RAN protein translation and accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If RAN translation is allowed to proceed, then normal protein synthesis continues, but toxic RAN proteins accumulate causing cellular dysfunction
Solution Approach 1:
The patent uses eIF2 modulating agents and PKR modulating agents as intermediary substances to selectively inhibit RAN translation. These agents act as mediators that interfere with the translation process by targeting specific factors (eIF2 and PKR) involved in RAN protein synthesis, thereby preventing toxic RAN protein accumulation while allowing normal protein synthesis to continue through alternative pathways
2Object-generated harmful factors
If eIF2α phosphorylation is inhibited, then RAN protein translation decreases, but global translation regulation is affected
Solution Approach 1:
The patent applies local quality by using selective modulating agents that specifically target eIF2α phosphorylation or PKR activity related to RAN translation. Rather than globally inhibiting all translation processes, the agents are designed to selectively interfere with the specific molecular mechanisms driving RAN protein synthesis, thereby reducing RAN protein accumulation while minimizing effects on overall cellular translation
3Object-generated harmful factors
If PKR activity is inhibited, then RAN translation is reduced, but cellular stress response is compromised
Solution Approach 1:
The patent employs partial action by using PKR modulating agents that partially inhibit PKR activity specifically in the context of RAN translation. The modulation is designed to be sufficient to reduce RAN protein production but not so strong as to completely abolish PKR's protective stress response functions, thereby achieving selective suppression of harmful RAN proteins while maintaining cellular defense mechanisms
Data Source
AI summary
Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.